AMRA MedicalAMRA Medical

AMRA Medical

Precision for Decision

  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Set Up
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Media
  • About Us
    • About AMRA
    • Our Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us

AASLD The Liver Meeting® 2023

MRI-Based Muscle Biomarkers linked to liver disease severity and progression

AMRA is attending at
AASLD The Liver Meeting® 2023
November 10, 2023 – November 14, 2023
Boston, MA, USA
Event Website

Why assess muscles in liver disease?

There is significant crosstalk between skeletal muscles and the liver, and a growing body of evidence places skeletal muscles at the center of the NAFLD pathogenic cascade 1. Importantly, sarcopenia is a common major complication in liver cirrhosis which negatively impacts outcomes in patients 2. Further, novel treatments for metabolic dysfunction have been shown in recent studies to be able to modulate muscle composition 3-5.

DID YOU KNOW?

AMRA’s latest research presents MAsS (Muscle Assessment Score) Biomarkers as a promising tool to identify physical frailty and sarcopenia and as a prognostic biomarker for liver disease.

Explore AMRA’s latest liver disease research presented at The Liver Meeting® leveraging AMRA’s MRI-based technology and biomarkers focusing along the spectrum of chronic liver disease.

Balkhed et al

●

●

#2077

NAFLD prevalence and predictors in patients with T2DM in primary care – Interim results from the EPSONIP study

Read more

Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 11

Balkhed et al

●

●

#2229

NAFLD, body and muscle composition profile in patients with T2D in primary care – Interim results from the EPSONIP study

Read more

Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 11

Healthy

Steatosis

Fibrosis

Cirrhosis

Post-transplant

Forsgren et al

●

#214

Muscle fat infiltration is elevated in prefrail and moderately physically impaired patients – interim results from the prospective multi-center cirrhosis cohort study ACCESS-ESLD

Read more

Republic Ballroom (Sheraton)
4:45 PM , Nov 13

Forsgren et al

●

#3090

Muscle volume z-score is lower in high-risk patients awaiting LT – interim results from a liver transplant waitlist natural history study

Read more

Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 12

Linge et al

●

●

#2263

Two year of wasting with metabolic disorders – initial results on muscle composition from the longitudinal UK Biobank imaging study

Read more

Poster Hall C (second level)
1:00 – 2:00 PM , Nov 11

Siddiqui et al​

●

#3002

Adipose Compartments Predict Severity of Portal Hypertension Among Patients with Cirrhosis

Read more

Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 12

Chavez et al

●

#2021

Characterizing Skeletal Muscle Composition and Function in Patients with Chronic Liver Disease

Read more

Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 11

Jamil et al

●

#2088

Patients with NASH Cirrhosis have similar muscle compositions as non-NASH patients as Assessed by Novel MRI-Based Muscle Assessment Technology

Read more

Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 11

Forsgren et al

●

#3089

Muscle fat infiltration, a potential risk marker, increases rapidly in patients with compensated liver cirrhosis – interim results from the prospective multi-center cirrhosis cohort study ACCESS-ESLD

Read more

Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 12

Advance clinical research with AMRA® Researcher including the novel MAsS (Muscle Assessment Score) biomarkers

AMRA’s MRI-based body composition analysis service, AMRA® Researcher, with its unique and patented technology and informatics platform, provides accurate and precise abdominal fat and muscle measurements. In addition to the volumetric measurements, AMRA provides muscle health biomarkers invariant to the confounding effects of sex and BMI, referred to as the Muscle Assessment Score (MAsS).6

Read more about AMRA® Researcher →

Read more about our clinical service AMRA®MAsS Scan →

AMRA® MAsS Scan utilizes AMRA® Profiler 4, which is a US FDA 510(k) cleared medical device and has an MDEL (Medical Device Establishment Licence) in Canada, where it is indicated for use as a magnetic resonance diagnostic device software application for non-invasive fat and muscle evaluation intended to be interpreted by a trained clinician to yield information that may assist in diagnosis.

Why MAsS?

The MAsS biomarkers, muscle volume z-score and muscle fat infiltration, can be used to detect muscle composition phenotypes such as the adverse muscle composition phenotype (high muscle fat and low volume).7

The adverse muscle composition phenotype has been shown to independently predict all-cause mortality in the general population and nonalcoholic fatty liver disease (NAFLD). Furthermore, muscle volume z-score and muscle fat infiltration have been linked to incident comorbidities, hospitalization, and poor functional performance in the general population and in NAFLD. 6-9

The link between muscle composition and chronic liver disease and outcomes, is well established in literature and the impact on muscle health by novel treatments of metabolic dysfunction is emerging. Therefore, these MAsS biomarkers may be crucial for clinical research investigating aspects of liver disease and potential targets for treatment thereof.

AMRA® MAsS Scan help you understand your patient’s muscle quality.

Resources

Publications

MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy

Webinar

Muscle-Liver Crosstalk and Sarcopenia in Chronic Liver Disease – Novel Techniques and Clinical Evidence

White Papers

Body Composition Profiling: The Stepping Stone Towards Precision Medicine in Clinical Trials

Webinar

Don’t Judge a Body by Its Cover – Body Composition Profiling in Clinical Trials

Follow us on social media

Follow AMRA Medical on social media for the latest updates in body composition and precision medicine. Please use your preferred social media platform below:

  • AMRA Medical on Linkedin
  • AMRA Medical on X
  • AMRA Medical on Facebook

Contact Us

Send us a message and we will happily provide more information or a quotation.

Contact Information

Latest News

  • AMRA Medical Launches AMRA® Profiler 4 in Sweden and Germany, Kickstarting Availability Campaign of AMRA® BCP Scan Service in the EU

    May 13, 2025

See All News →

References

1. Chakravarthy MV, Siddiqui MS, Forsgren MF, Sanyal AJ. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne). 2020;11:592373.

2. Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(3):1611-44.

3. Patel KV, Pandey A, Ayers C, J. L, Dahlqvist Leinhard O, Joshi PH, et al. Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity: a randomised clinical trial. Diabetologica. 2022;65(Suppl 1):S59.

4. Linge J, Neeland I, Dahlqvist Leinhard O, Sattar N, Fernandez Lando L, Bray R, et al. Tirzepatide achieves significant weight loss without adverse effects on muscle composition (SURPASS-3 MRI). Diabetologia. 2023;66(Suppl 1):S3.

5. Sattar N, Linge J, Neeland I, Dahlqvist Leinhard O, Fernandez Lando L, Bray R, et al. Tirzepatide reduces muscle fat infiltration relative to insulin degludec in people with type 2 diabetes (SURPASS-3 MRI). Diabetologia. 2023;66(Suppl 1):S3.

6. Linge J, Heymsfield SB, Dahlqvist Leinhard O. On the Definition of Sarcopenia in the Presence of Aging and Obesity-Initial Results from UK Biobank. J Gerontol A Biol Sci Med Sci. 2020;75(7):1309-16.

7. Linge J, Nasr P, Sanyal AJ, Dahlqvist Leinhard O, Ekstedt M. Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD. JHEP Rep. 2023;5(3):100663

8. Linge J, Petersson M, Forsgren MF, Sanyal AJ, Dahlqvist Leinhard O. Adverse muscle composition predicts all-cause mortality in the UK Biobank imaging study. J Cachexia Sarcopenia Muscle. 2021;12(6):1513-26.

9. Linge J, Ekstedt M, Dahlqvist Leinhard O. Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. JHEP Rep. 2021;3(1):100197.

AMRA Medical
Follow us

About

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

  • Data Privacy Policy
  • Cookie Policy

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contact

  • info@amramedical.com
  • +46 (0) 13 16 26 00
  • Contact Our Support

Newsletter

© 2025 AMRA Medical AB
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}